0MTD.LSE Swedish Orphan Biovitrum AB

Healthcare Commercial Services & Supplies London Exchange
- SEK
Market cap
-
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2023.

Is 0MTD.LSE undervalued?

Graham number

The Graham number of Swedish Orphan Biovitrum AB cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Swedish Orphan Biovitrum AB fundamental analysis

No fundamental analysis for Swedish Orphan Biovitrum AB yet.

Swedish Orphan Biovitrum AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal no…

Full company profile